The Role and Mechanism of SGLT2 Inhibitors in Chronic Kidney Disease
Drug Design, Development and Therapy · 2026
DOI: 10.2147/dddt.s648280 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Jiaqian Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Hypoglycemic Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People's Republic of China.
ORCID-Profile: Tianbiao Zhou
Zitieren
APA
Xie, J., Liu, Y., Zhao, Y., Wang, Y., & Zhou, T. (2026). The Role and Mechanism of SGLT2 Inhibitors in Chronic Kidney Disease. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s648280
Vancouver
Xie J, Liu Y, Zhao Y, Wang Y, Zhou T. The Role and Mechanism of SGLT2 Inhibitors in Chronic Kidney Disease. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s648280
BibTeX
@article{Xie2026,
author = {Xie, Jiaqian and Liu, Yuqi and Zhao, Yi and Wang, Ying and Zhou, Tianbiao},
title = {The Role and Mechanism of SGLT2 Inhibitors in Chronic Kidney Disease},
journal = {Drug Design, Development and Therapy},
year = {2026},
doi = {10.2147/dddt.s648280}
}
EUVIMED